Abstract
Despite our increasing understanding of the genomic heterogeneity of non-small cell lung cancer (NSCLC), patients with locally advanced inoperable disease are treated with the same dose of radiation therapy (RT). Tissue-based analyses have identified likely biomarkers of RT response. We evaluated the feasibility of prospective molecular profiling with liquid biopsy ctDNA testing to identify genomic markers of RT sensitivity and resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
